levofloxacin
Commercial- Indications
- Cystic fibrosis, Chronic pulmonary infections
Company intelligence / Profile preview
Mpex Pharmaceuticals, Inc.
San Diego, California, United Statesmolsoft.com ↗
- Ownership
- Private
- Employees
- ~82
- Development stage
- Commercial
01
Overview
Mpex Pharmaceuticals developed antibacterial drugs to combat multi-drug resistant bacterial pathogens. Their lead product Aeroquin® (MP-376), a proprietary aerosol formulation of levofloxacin, was in clinical development for respiratory infections. The company was acquired by Adare Pharmaceuticals in April 2011.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesAntibiotics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Molsoft, LLC
Beyond the preview
Go deeper on Mpex Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mpex Pharmaceuticals, Inc..